A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved ... The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven thalassaemia ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can ... to begin an early stage trial of CTX001, a gene therapy derived from ...

The approval of Vertex and partner CRISPR Therapeutics CRSP one-shot gene therapy Casgevy for two blood disorders, sickle ...

Furthermore, CRISPR Therapeutics will share the profits generated from Casgevy with Vertex Pharmaceuticals, with which it developed the medicine; Vertex is entitled to 60% of the program profits.

CRISPR Therapeutics' stock is down 19% since December ... but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy ...

To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug ...